← Back to Search

Macugen Injections for Age-Related Macular Degeneration

Phase 4

Waitlist Available

Research Sponsored by Eyetech Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients who have had at least 1 but not more than 3 prior treatments for AMD

Patients with subfoveal CNV secondary to AMD

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing if Macugen is effective and safe to use as maintenance therapy for Neovascular Age-Related Macular Degeneration for patients who have had success with other treatments.

Who is the study for?

This trial is for people with a condition called Age-Related Macular Degeneration (AMD) who have had some success with up to three previous treatments. They must have a specific type of AMD where abnormal blood vessels grow under the retina, but can't join if they have eye conditions like cataracts that could affect vision or scars in the central part of their retina.Check my eligibility

What is being tested?

The study is testing the safety and effectiveness of an eye injection called Macugen when given every six weeks as ongoing treatment for AMD. It's aimed at those who've seen improvements from earlier AMD therapies.See study design

What are the potential side effects?

While not specified here, common side effects of similar eye injections may include eye irritation or pain, blurred vision, feeling like something is in your eye, and possible bleeding inside the eye.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had 1 to 3 treatments for age-related macular degeneration.

Select...

I have AMD-related vision loss due to abnormal blood vessels.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Eyetech PharmaceuticalsLead Sponsor

14 Previous Clinical Trials

2,087 Total Patients Enrolled

PfizerIndustry Sponsor

4,567 Previous Clinical Trials

10,907,303 Total Patients Enrolled

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00354445 — Phase 4

Age-Related Macular Degeneration Research Study Groups:

Age-Related Macular Degeneration Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00354445 — Phase 4

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00354445 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment initiatives currently ongoing for this investigation?

"This particular clinical trial is not presently enrolling participants, as indicated by the information on clinicaltrials.gov. It was initially posted on June 1st 2006 and last revised January 12th 2007; however, there are 159 other studies currently accepting applicants."

Answered by AI

To what degree is this therapy perilous for individuals?

"After assessing the available data, Power's team has assigned this treatment a 3 out of 3 for safety due to it being in Phase 4 trials and having received approval."

Answered by AI

Recent research and studies

British Journal of OphthalmologyJournal

Pegaptanib Sodium as Maintenance Therapy in Neovascular Age-related Macular Degeneration: The LEVEL Study

Friberg, T. R., M. Tolentino, and for the LEVEL Study Group. 2010. “Pegaptanib Sodium as Maintenance Therapy in Neovascular Age-related Macular Degeneration: The LEVEL Study”. British Journal of Ophthalmology. BMJ. doi:10.1136/bjo.2009.174946.

clinicaltrials.govStudy

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

2006. "A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00354445.